Ultra Clean Holdings reported record Q3 2026 revenue of $759 million, a 49% increase from Q3 2025, driven by strong demand in semiconductor components and services. GAAP gross margin was 16.9%, with GAAP EPS at $0.85, reflecting solid operational performance and efficient scaling. The company expects Q4 revenue between $800 million and $860 million and anticipates further earnings growth, positioning itself to benefit from AI-driven industry expansion. This strong quarter highlights Ultra Clean's strategic focus on innovation and customer collaboration to capture long-term value.
Ultra Clean's Q3 2026 revenue reached a record $759 million, marking a 49% increase from the previous year. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 28, 2026 02:21 WIB: out of 150 priced US tech stocks, 83 rose and 67 fell. Notable movers include CRDO at USD 166.86 (+10.39%) with 86% sell orders, BBAI at USD 2.34 (+10.38%), and APLD at USD 19.64 (+10.15%) with balanced buy/sell activity and typical hold times around 24-30 days.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
